116 related articles for article (PubMed ID: 2940092)
1. In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assay.
Dodion P; Sanders C; Rombaut W; Rozencweig M; Kitt MM; Kenis Y; Klastersky J
Eur J Cancer Clin Oncol; 1986 Mar; 22(3):245-9. PubMed ID: 2940092
[TBL] [Abstract][Full Text] [Related]
2. Role of oxygen free radical formation in the mechanism of menogaril resistance in multidrug resistant tumor cells.
Sinha BK; Atwell J; Politi PM
Chem Biol Interact; 1990; 76(1):89-99. PubMed ID: 2168296
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Long HJ; Powis G; Schutt AJ; Moertel CG
Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
[TBL] [Abstract][Full Text] [Related]
6. Menogaril: a new anthracycline agent entering clinical trials.
McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Dodion P; Egorin MJ; Engisch KL; Bachur NR
Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
[TBL] [Abstract][Full Text] [Related]
9. Intracellular uptake of 7-con-o-methylnogarol and adriamycin by cells in culture and its relationship to cell survival.
Bhuyan BK; McGovren JP; Crampton SL
Cancer Res; 1981 Mar; 41(3):882-7. PubMed ID: 6450639
[No Abstract] [Full Text] [Related]
10. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.
Wierzba K; Sugimoto Y; Matsuo K; Toko T; Takeda S; Yamada Y; Tsukagoshi S
Jpn J Cancer Res; 1990 Aug; 81(8):842-9. PubMed ID: 2144516
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy.
Long HJ; Schaid DJ; Schutt AJ; Ingle JN; Loprinzi CL; Edmonson JH
Am J Clin Oncol; 1988 Oct; 11(5):524-7. PubMed ID: 2972192
[TBL] [Abstract][Full Text] [Related]
12. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo.
Adams EG; Bhuyan BK
Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401
[TBL] [Abstract][Full Text] [Related]
13. P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.
Badiner GJ; Moy BC; Smith KS; Tarpley WG; Groppi VE; Bhuyan BK
Br J Cancer; 1990 Sep; 62(3):378-84. PubMed ID: 2145026
[TBL] [Abstract][Full Text] [Related]
14. Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.
Levey BA; Ruiz E; Rogerson B; Lehotay DC; Levey GS
Cancer Treat Rep; 1980; 64(10-11):1127-8. PubMed ID: 6109566
[No Abstract] [Full Text] [Related]
15. Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group.
Sessa C; Kaye SB; Renard J; ten Bokkel Huinink W; Cavalli F
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):751-2. PubMed ID: 2523809
[No Abstract] [Full Text] [Related]
16. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
Buckner JC; Edmonson JH; Ingle JN; Schaid DJ
Am J Clin Oncol; 1989 Oct; 12(5):384-6. PubMed ID: 2529759
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of intravenous menogaril in patients with advanced breast cancer.
Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
20. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]